Scientific innovation's two valleys of death: How blood and tissue banks can help to bridge the gap

Stem Cells and Development

Volumn 23, Issue , 2014, Pages 68-72

  Thompson, Sean D A ^a  

^a Department of Business Development Biobridge Global   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL;

APPLIED RESEARCH; ARTICLE; BASIC RESEARCH; BIOTECHNOLOGY; BLOOD BANK; COMMERCIAL PHENOMENA; DEVELOPMENTAL STAGE; DRUG INDUSTRY; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE FACILITY; HUMAN; IN VIVO STUDY; INVESTMENT; LICENCE; LICENSING; PATENT; PRODUCT DEVELOPMENT; QUALITY CONTROL; RISK REDUCTION; ECONOMICS; INTERNATIONAL COOPERATION; MASS COMMUNICATION; STATISTICAL MODEL; STEM CELL RESEARCH; UNITED STATES;

BLOOD BANKS; DIFFUSION OF INNOVATION; FINANCING, GOVERNMENT; HUMANS; INTERNATIONAL COOPERATION; MODELS, ECONOMIC; RESEARCH SUPPORT AS TOPIC; STEM CELL RESEARCH; TISSUE BANKS; UNITED STATES;

EID: 84919348913     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0379     Document Type: Article

References (4)

1. Francis FS. (2013). Executive Summary Budget Mechanism. National Institutes of Health FY 2013 Congressional Justification: ES-31.
2. Butler D. (2008). Translational research: crossing the valley of death. Nature 453:840-842.
3. Francis FS. (2013). Executive Summary Budget Mechanism. National Institutes of Health FY 2013 Congressional Justification: ES-16.
4. Steinmetz KL and EG Spack. (2009). The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurol 9(Suppl 1):S2.